jili 63 free 120

jili 63 free 120 President-elect Donald Trump announced Friday he would work to end the "inconvenient" custom of moving clocks forward one hour every spring, which he said was imposing an unnecessary financial burden on the United States. "The Republican Party will use its best efforts to eliminate Daylight Saving Time, which has a small but strong constituency, but shouldn't! Daylight Saving Time (DST) is inconvenient, and very costly to our Nation," Trump posted on his website, Truth Social. DST was adopted by the federal government during World War I but was unpopular with farmers rushing to get produce to morning markets, and was quickly abolished. Many states experimented with their own versions but it wasn't reintroduced nationwide until 1967. The Democratic-controlled US Senate advanced a bill in 2022 that, like Trump's plan, would bring an end to the twice-yearly changing of clocks, in favor of a "new, permanent standard time." But The Sunshine Protection Act called for the opposite switch -- moving permanently to DST rather than eliminating it -- to usher in brighter evenings, and fewer journeys home in the dark for school children and office workers. The bill never made it to President Joe Biden's desk, as it was not taken up in the Republican-led House. It had been introduced in 2021 by a Republican, Florida Senator Marco Rubio, who is about to join the incoming Trump administration as secretary of state. He said studies had shown a permanent DST could benefit the economy. Either way, changing to one permanent time would put an end to Americans pushing their clocks forward in the spring, then setting them back an hour in the fall. Colloquially the practice is referred to as "springing" forward and "falling" back. The clamor has increased in recent years to make DST permanent especially among politicians and lobbyists from the Northeast, where frigid conditions are normal in the early winter mornings. "It's really straightforward. Cutting back on the sun during the fall and winter is a drain on the American people and does little to nothing to help them," Rubio said in a statement ahead of the vote. "It's time we retire this tired tradition." Rubio said the United States sees an increase in heart attacks and road accidents in the week that follows the changing of the clocks. Any changes would be unlikely to affect Hawaii and most of Arizona, the Navajo Nation, American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the US Virgin Islands, which do not spring forward in summer. ft/nro

Bushra Bibi granted interim bail in four Nov 26 protest cases

Wheaton Precious Metals Corp. (NYSE:WPM) Shares Acquired by MAI Capital Management

Share this Story : Back to work! Ottawa Senators' break is over and playoff chase continues Copy Link Email X Reddit Pinterest LinkedIn Tumblr Breadcrumb Trail Links Ottawa Senators Hockey NHL Senators Extra Back to work! Ottawa Senators' break is over and playoff chase continues Mads Sogaard did face the Toronto Marlies on Boxing Day so that's a good sign that Linus Ullmark will be okay. The club wouldn't have risked injury with Sogaard if he was needed in Ottawa. Author of the article: Bruce Garrioch Published Dec 26, 2024 • 4 minute read Join the conversation You can save this article by registering for free here . Or sign-in if you have an account. Linus Ullmark Photo by Chris Tanouye/Freestyle Photo / GETTY IMAGES Article content The Ottawa Senators will return to work on Friday morning with a simple task: Stay in the hunt. Sitting in a playoff spot at the National Hockey League’s mandated three-day holiday break for the first time since 2016-17, the Senators will prepare to face the Winnipeg Jets on Saturday night at the Canada Life Centre with five games left on this lengthy nine-game road trip. Advertisement 2 Story continues below This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Exclusive articles from Elizabeth Payne, David Pugliese, Andrew Duffy, Bruce Deachman and others. Plus, food reviews and event listings in the weekly newsletter, Ottawa, Out of Office. Unlimited online access to Ottawa Citizen and 15 news sites with one account. Ottawa Citizen ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. Support local journalism. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Exclusive articles from Elizabeth Payne, David Pugliese, Andrew Duffy, Bruce Deachman and others. Plus, food reviews and event listings in the weekly newsletter, Ottawa, Out of Office. Unlimited online access to Ottawa Citizen and 15 news sites with one account. Ottawa Citizen ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Sign In or Create an Account Email Address Continue or View more offers If you are a Home delivery print subscriber, online access is included in your subscription. Activate your Online Access Now Article content The Senators will play 22 games in the next 42 days before the NHL takes a break for the first Four Nations Face-Off, so this stretch will determine whether this club is a pretender or a contender. The road ahead won’t be easy for the Senators who have posted an 18-14-2 record. With 48 games left on the schedule and the Senators in the No. 2 wildcard spot in the East, here are some keys to watch. ULLMARK’S HEALTH We’ll find out Linus Ullmark’s status when the Senators hit the ice on Friday. He left the club’s 3-1 loss after the first. Coach Travis Green told reporters “his back tightened up so felt it was best that he came out.” If it were just back spasms then the break would have been good for the 31-year-old Ullmark to get rested and he should be ready to play. He didn’t look any worse for wear in a photo posted on social media on Christmas Eve (Tuesday) so that’s a good sign. The hope is he’ll be ready to play against the Jets. Ullmark has played a pivotal role in the club’s success. He’s been the NHL’s best goalie in the last month, with an 8-0-1 record in his last 10 appearances and a 1.48 goals-against average, plus an impressive .952 save percentage and two shutouts. Sports Get the latest sport headlines and breaking news. There was an error, please provide a valid email address. Sign Up By signing up you consent to receive the above newsletter from Postmedia Network Inc. Thanks for signing up! A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sports will soon be in your inbox. We encountered an issue signing you up. Please try again Article content Advertisement 3 Story continues below This advertisement has not loaded yet, but your article continues below. Article content We’ll also find out if backup Anton Forsberg, who has missed four straight games with a lower-body injury he suffered on Dec. 14 in the gym before a game against the Pittsburgh Penguins, is ready. If Forsberg can’t suit up then Leevi Merilainen will be recalled from the club’s American Hockey League affiliate in Belleville and if Ullmark is injured then Mads Sogaard is also expected to be brought up. But Sogaard did face the Toronto Marlies on Boxing Day at Scotiabank Arena so that’s a good sign that Ullmark will be okay. The club wouldn’t have risked injury with Sogaard if he was needed in Ottawa. HEALTHY RETURNS It’s been a month since defenceman Artem Zub broke his foot blocking a shot on Nov. 23 against the Vancouver Canucks. He was placed on long-term injury reserve with a timeline of eight-to-12 weeks for a return. Steve Staios, the club’s president of hockey operations and general manager, initially tried to acquire a blueliner, but felt the cost was too high on the market and opted to have the answers come from within. That’s forced veteran Travis Hamonic to play in a top-four role as Jake Sanderson’s partner and that wasn’t expected at the start of the season while Jacob Bernard-Docker has played with rookie Tyler Kleven. Advertisement 4 Story continues below This advertisement has not loaded yet, but your article continues below. Article content The Senators have posted an 8-2-1 record in December and a lot of that is thanks to Ullmark’s stellar play. The club’s six-game winning streak came to an end in Edmonton. Winger David Perron has only suited up for nine games this season after signing as a free agent in the off-season. The 36-year-old missed a month for personal reasons and is now sidelined with an undisclosed upper-body injury with no timeline for his return. Getting Perron back would give the club some much-needed depth and an option to play in the top six. Ridly Greig will be a good player down the road, but he’s not ready for the role he’s played at times. BUYER OR SELLER The NHL trade deadline is set for March 7 at 3 p.m. EST. Staios should be ready to determine by the February break whether he’ll add or subtract from the Senators at that point. If the Senators are going to buy, the club’s needs haven’t changed since training camp got underway in September. The experiments in the top six haven’t worked and if Perron isn’t healthy then that’s an area that needs to be addressed. Adam Gaudette has played there at various times and he could be a solution but he’s also been used in Advertisement 5 Story continues below This advertisement has not loaded yet, but your article continues below. Article content The back end is an area where Staois has been looking for depth all season. He studied the possibility of picking up someone on waivers before the year got underway, but couldn’t find the right fit. Several league executives told Postmedia before the NHL’s roster freeze went into effect on Dec. 22 that the Senators were looking for a defenceman and had been for weeks. There is talk the Senators kicked tires on Nashville defenceman Alexandre Carrier before he was dealt to the Montreal Canadiens. Perhaps, Staios looks at veteran Habs’ blueliner David Savard as a possibility. We don’t know if Habs’ GM Kent Hughes would want to deal with the Senators but Savard, 34, won a Stanley Cup with the Tampa Bay Lightning and would fit the mould of what the Senators want. bgarrioch@postmedia.com Recommended from Editorial It's anybody's guess when Linus Ullmark will return to Ottawa Senators net How Gord Miller became the voice of the world junior hockey championship Article content Share this article in your social network Share this Story : Back to work! Ottawa Senators' break is over and playoff chase continues Copy Link Email X Reddit Pinterest LinkedIn Tumblr Comments You must be logged in to join the discussion or read more comments. Create an Account Sign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. Trending New Ottawa restaurants in 2025 from three top chefs will offset a year rife with closures Life Ottawa police investigate Christmas Day homicide in Hintonburg Local News Everything Ottawa needs to know about the world junior hockey championship News Frustrated Porter passengers stuck 2 1/2 hours on YOW tarmac Local News Fraser: My favourite Ottawa photos of 2024 capture love, loss and a lot of protests News Read Next Latest National Stories Featured Local Savings

Christmas time is seriously the happiest time of the year. There’s just something about the twinkling lights, holiday music, and festive vibes that make everything feel a little more magical. Whether you’re out shopping for gifts or just soaking up the holiday spirit, it’s hard not to get caught up in the joy of it all. One of the best parts? Hitting up restaurants and bars that go all out with their Christmas decorations. It’s like stepping into a real-life winter wonderland, and who doesn’t love that? From cozy fireplaces and garlands draped over every corner to sparkling Christmas trees and even holiday-themed menus, festive restaurants are the perfect way to level up your holiday experience. READ MORE: Ocean City, NJ Is Shockingly The State's Drunkest City There’s nothing better than sipping on a themed cocktail like a peppermint martini or a spiced cider, while surrounded by all the holiday magic. Plus, it’s such a fun way to make some memories with family and friends. Everyone’s in a good mood, the vibe is warm and cheerful, and it just feels like Christmas is truly in the air. New Jersey has its fair share of festive spots that go all out for the holidays, but there’s one restaurant that truly takes the cake. It’s the kind of place that feels like it belongs in a Hallmark movie, and it’s impossible not to smile when you walk in. Ready to find out where it is? Let’s dive into the most festive restaurant for Christmas in New Jersey! What Is The Most Festive Restaurant This Christmas Season in 2024? The Parkside Social in Verona, New Jersey has to be the most festive restaurant in the state. This spot goes all out for the holidays and is full of the most amazing decorations I’ve ever seen. They call it “Miracle on Bloomfield” for the holidays and it looks like such a great spot to check out. Restaurants You Loved in NJ But Don't Exist Anymore I'm sure you have memories of having dinner at some of these places and secretly wish it would make a comeback., right? How many have you been too? Gallery Credit: Chris Rollins Tis' the Season. Here are the Spirit Christmas Stores in NJ & PA You love Spirit Halloween so much that a bunch of locations are turning into Spirit Christmas once Spooky Szn is over. Gallery Credit: Chris RollinsYear-End Reflections And 2025 Outlook: The Role of Small Caps/Mid Caps And Their Potential In Wealth Creation

Maryland Gov. Wes Moore and Baltimore Mayor Brandon Scott hope a newly planned weeks-long festival will draw more fans, and revenue, to the Preakness Stakes and the area as the city prepares to host the second jewel of the Triple Crown. The biggest event on Baltimore’s spring calendar has lost money in recent years. Crowds have dwindled from an average of more than 100,000 in the decade before the coronavirus pandemic to 63,423 on Friday and Saturday last May. Young people have turned away from thoroughbred racing and the signature event, despite the presence of headlining musical acts such as and . Moore and Scott hope to turn the tide leading up to the 150th running of the race on May 17 — the final turn around the current version of the soon-to-be renovated Pimlico Race Course. “Preakness is a chance for Baltimore to show off,” Moore said at a presentation Wednesday on the sixth floor of the warehouse at Camden Yards. “And that’s what’s going to happen with Preakness 150.” Shortly after next year’s race, bulldozers and wrecking balls will begin demolishing the dilapidated facility as part of a expected to have a new Pimlico ready to host the Preakness by 2027. The refurbished track, in tandem with a new off-site training facility, is expected to become the headquarters for Maryland thoroughbred racing by the end of that year. Wednesday’s presentation was short on specifics, with festival organizers saying only that the buildup to the Preakness will last for months and that a list of events — including free and ticketed cultural gatherings, arts activities, and a headline concert — will be released in early 2025. But the co-chairs of the initiative are heavy hitters, from the first lady Dawn Moore to Orioles owner David Rubenstein to Stronach Group CEO Belinda Stronach, whose Canadian company still owns the Preakness despite having sold Pimlico to the state earlier this year. They said its events will “deliver experiences that equitably enhance economic growth, promote tourism and inspire civic pride through collaborative work with small-, minority-, women- and veteran-owned businesses.” Dawn Moore said the seed of the idea hit her after she and her husband visited the Kentucky Derby two years ago and recognized that the parties and community events leading up to the first jewel of the Triple Crown take over Louisville for weeks leading up to the actual race. Dec 11, 2024: Baltimore City Mayor Brandon Scott speaks at a media event at the Warehouse at Camden Yards previewing plans for the 150th running of the Preakness Stakes, a Preakness Festival and future plans for Pimlico Race Course and the Park Heights community. Listening are Maryland First Lady Dawn Moore, Governor Wes Moore and David Rubenstein, owner of the Baltimore Orioles. (Kim Hairston/Staff) Maryland First Lady Dawn Moore speaks at a press event to preview plans for the 150th running of the Preakness Stakes. A Preakness Festival, future plans for Pimlico Race Course and the Park Heights community were highlighted at the event held at the Warehouse at Camden Yards. (Kim Hairston/Staff) Maryland First Lady Dawn Moore speaks at a press event to preview plans for the 150th running of the Preakness Stakes. A Preakness Festival, future plans for Pimlico Race Course and the Park Heights community were highlighted at the event held at the Warehouse at Camden Yards. (Kim Hairston/Staff) Baltimore Mayor Brandon Scott helped announce the creation of a new weeks-long festival designed to draw more attention to the Preakness Stakes. (Kim Hairston/Staff) Maryland Governor Wes Moore speaks at a press event about plans for the 150th running of the Preakness Stakes including a Preakness Festival, future plans for Pimlico Race Course and the Park Heights community. (Kim Hairston/Staff) From left, Terry Hasseltine, executive director of the Maryland Sports Commission and president of Sports and Entertainment Corporation of Maryland, Governor Wes Moore, First Lady Dawn Moore and David Rubenstein, owner of the Baltimore Orioles, watch a video promoting the Preakness Festival for the 150th running of the Preakness Stakes. The press event is held at the Warehouse at Camden Yards. (Kim Hairston/Staff) Maryland Governor Wes Moore speaks at a press event about plans for the 150th running of the Preakness Stakes including a Preakness Festival, future plans for Pimlico Race Course and the Park Heights community. (Kim Hairston/Staff) Terry Hasseltine, executive director of the Maryland Sports Commission and president of Sports and Entertainment Corporation of Maryland speaks about plans for the 150th running of the Preakness Stakes during a press event at the Warehouse at Camden Yards. (Kim Hairston/Staff) Dec 11, 2024: Baltimore City Mayor Brandon Scott speaks at a media event at the Warehouse at Camden Yards previewing plans for the 150th running of the Preakness Stakes, a Preakness Festival and future plans for Pimlico Race Course and the Park Heights community. Listening are Maryland First Lady Dawn Moore, Governor Wes Moore and David Rubenstein, owner of the Baltimore Orioles. (Kim Hairston/Staff) “We could do it better,” she recalled telling the governor. “Well, go do it then,” she remembered him responding. One of the festival’s other co-chairs, Stella May Contracting chief financial officer Christian Johansson, noted that the Derby generated $396 million in economic impact for Kentucky in 2023 while the most recent study on the Preakness showed it generated just $41 million for Maryland. “The main reason is the Derby isn’t one or two days,” Johansson said. “Maryland historically has not fully captured the economic impact the Preakness could have.” Rubenstein donated to supplement funds from the Maryland Lottery’s major events fund to help get the new festival off the ground. The Orioles owner said he was dining with the Moores when the first lady ran the play by him. “That’s a pretty clever idea,” Rubenstein recalled thinking. “How come nobody else thought of that before?” He noted that he grew up a mile from Pimlico but never visited the track as a child because he wasn’t old enough. He promised to be there to celebrate the winner in 2025. Related Articles Scott grew up even closer, in Park Heights, but recalled not feeling welcome at the Preakness, which he did not attend until 2019. He said that this new initiative is about forging deeper connections between the event and the community around it. He and Moore noted that the Pimlico rebuild project includes $10 million for affordable housing and job creation in surrounding neighborhoods and that the festival will play off that mission. “We want to show the world the real and true Baltimore,” the mayor said. “One that is resilient, fun and on the rise, one that is the home of excellence but in particular, this Old Bay-sprinkled Black excellence. “That’s not what Preakness has always been. It hasn’t always been a place where we felt welcome. It was held in Northwest Baltimore, but it was very clear that it wasn’t Northwest Baltimore. But over the past few years ... we’ve begun to change that narrative.”-- Reduces total emissions by approximately 14 percent since base year -- -- Decreases water withdrawal by approximately 17 percent since base year -- -- Achieves lost-time injury rate of 0.28, representing an approximate 32 percent reduction from prior year -- MORRISVILLE, N.C. , Dec. 11, 2024 /PRNewswire/ -- Pyxus International, Inc. (OTC Pink: PYYX), a global value-added agricultural company, today published its Fiscal Year 2024 Sustainability Report detailing the measurable impacts of the Company's sustainability initiatives as it progresses toward achieving its global targets. "Fiscal year 2024 was an exceptional year for Pyxus and this report highlights the positive impacts of our environmental and social initiatives, including collaboration with our contracted growers to reduce scope 3 emissions, improvement of our employee health and safety practices, and providing support to those in need," said Pyxus President and CEO Pieter Sikkel . "We remain committed to viewing all aspects of our business through a sustainable lens, helping us progress against our targets while delivering value to our stakeholders, the environment and the communities in which we operate." Notable fiscal year 2024 sustainability achievements include: Minimal Environmental Impact Support for People and Communities Ethical and Responsible Business In preparation of this year's report, Pyxus externally verified 11 global key performance indicators (KPIs) associated with its targets, up from three KPIs in the prior year. The report was prepared with reference to Global Reporting Initiative (GRI) Standards, aligns with the United Nations Sustainable Development Goals and discloses the Company's sustainability performance from April 1, 2023 , to March 31, 2024 . About Pyxus International, Inc. Pyxus International, Inc. is a global agricultural company with more than 150 years of experience delivering value-added products and services to businesses and customers. Driven by a united purpose—to transform people's lives, so that together we can grow a better world—Pyxus International, its subsidiaries and affiliates, are trusted providers of responsibly sourced, independently verified, sustainable, and traceable products and ingredients. For more information, visit www.pyxus.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/pyxus-releases-fiscal-year-2024-sustainability-report-302329534.html SOURCE Pyxus International, Inc.

None

Founded as a family business in 1985, the expanding Surrey-based firm has increased year-on-year revenue thanks to a successful ‘quick and able’ approach to customer orders worldwide. ‘Quick and able’ is designed to meet the needs of global markets through continuous improvements in manufacturing capacity coupled with a fast 24/7 distribution model based on direct supply from the UK. The strategy has seen exports grow by more than 70% in the last five years, taking the level of international sales to 73% of revenues overall. Amazon Filters is one of Europe’s leading manufacturers of high-quality liquid and gas filters. These are essential for removing contamination across process industries including municipal water, food and beverage, pharma, healthcare, chemicals and coatings, oil and gas, and green hydrogen production. The product range includes membrane and depth filter cartridges and capsules, stainless steel filters and carbon and pleated filters, and filter housings. On bespoke engineering projects, such as emergency action to tackle outages in the public water supply or wear and tear on filtration systems on offshore oil production platforms, the company works with customers to develop unique filter formats that address specific requirements in-situ. Managing Director Neil Pizzey, a chartered manufacturing engineer, says the firm has grown organically. “The recipe for success remains the same today as it was when my father Mike founded the company,” Neil explains. “It’s all about being close to customers and showing we are more in tune with their needs than larger multinationals.” The core business boils down to knowledge in the form of a physical product, says Neil. “Nobody buys a filter because it looks nice on the mantelpiece. It’s there to solve a problem. So, recognising what that is, and helping people to overcome it, is how we operate. My father understood this, and we have always made sure we have the expertise and knowledge to help customers solve their issue.” Amazon Filters has made a series of strategic appointments and promotions to strengthen its global reach this year. These have added expertise in areas such as product design, fabrication, quality management and the marketing of solutions to the healthcare and pharma sectors. In a specific drive towards further export growth, a dedicated business head for central Europe has been appointed through the firm’s German subsidiary. The new hires and promotions complement and reinforce the ‘quick and able’ programme of capital investment under way at the main Camberley production centre. This has included innovations such as a motorised welding platform, an expanded floor area for cartridge production, a range of automated assembly equipment, a new metalwork facility and a storage and stock control platform. Thanks to the investment programme, Amazon Filters can now make and deliver a typical annual volume of more than three million meltblown cartridges and one million pleated cartridges, demonstrating a significant increase in capacity, flexibility and speed of response to bespoke orders. Forty years on from its founding, Amazon Filters can today list key sales regions in Europe, Brazil, North America, Southeast Asia, South Africa and Australia. As well as a dedicated production, research and development and sales hub in Poland, the firm employs in-region territory managers in France, Italy and Malaysia with support from the UK based team. Neil believes Amazon Filters has a ‘strong story to tell’ about the benefits of robust filtration solutions for sustainability. “A good quality filter lasts longer, reduces waste and minimises system contamination,” he says. “This directly helps industries under pressure to make better use of resources, for example because of regulatory regimes that drive environmental standards and actions.” Reflecting the same environmental focus, Amazon Filters this year became the first UK filter maker to use polypropylene made from renewable resources to produce meltblown filter media. Effectively lowering the carbon footprint of each filter, the firm launched sustainable polypropylene versions of four ranges widely used in critical liquid filtration processes. Guiding all activity is a range of ISO-accredited and other international quality standards that demonstrate safety, reliability and excellence in customer service. Among objectives for future growth, the firm is targeting more work in the global hydrogen production industry. “It’s an ongoing journey,” says Neil. “By investing in people and process and being the best we can be, we improve our customer offering and develop key markets.” For more information, visit www.amazonfilters.co.ukVERMILLION, S.D. (AP) — Aidan Bouman threw a 25-yard touchdown pass to Javion Phelps with 12 seconds left and South Dakota defeated FCS top-ranked North Dakota State 29-28 on Saturday to claim a share of its first Missouri Valley Football Conference championship. The Coyotes (9-2, 7-1) trailed 28-17 when Bouman threw deep to Jack Martens for a 40-yard touchdown with 3:22 remaining. They got the ball back with 1:16 left and six plays later Bouman was sacked. The Coyotes quickly lined up and Bouman found Phelps alone 2 yards shy of the end zone along the left sideline and he easily scored. South Dakota won its first game against the Bison in Vermillion since a four-overtime thriller in 2002. The Bison had won the last five meetings in the DakotaDome. The Coyotes took a 14-0 lead on two Travis Theis rushing touchdowns but the Bison (10-2, 7-1) tied the game with two scores in the final 2:26 of the first half, a 23-yard pass from Cam Miller to Braylon Henderson and a 3-yard TD run by Miller. Miller scored from 2 yards out late in the third quarter and CharMar Brown completed a 20-play, 99-yard drive that took nearly 11 minutes with a 1-yard score for a 28-17 Bison lead with just over four minutes to go. Bouman was 18-of-30 for 271 yards and two touchdowns. Miller was 9-of-21 passing with one touchdown and he rushed for 82 yards and another score. AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football . Sign up for the AP’s college football newsletter: https://apnews.com/cfbtop25

Our community members are treated to special offers, promotions and adverts from us and our partners. You can check out at any time. More info Ardal O’Hanlon has shared a warning for new Death In Paradise star Don Gilet, describing the role as "gruelling" and difficult to sustain for more than a few years. O’Hanlon, who played DI Jack Mooney from 2017 to 2020, revealed he often worked 12-hour days, six days a week, during his time on the hit BBC drama. Reflecting on his experience while promoting his upcoming stand-up tour, Not Himself, Ardal admitted that the intense filming schedule in Guadeloupe took a toll, both physically and mentally, reports the Mirror. "God, that was tough. People don’t believe you when you tell them how challenging it is," he said. "I’m so grateful for the part—it was life-changing—but it’s not just about playing the lead in a popular show. It’s a complete lifestyle shift." He explained the demands of the role: "Coming from a place where I barely leave the house to living outdoors for six months a year was such a radical change for me. It was gruelling because of the sheer workload. You’re constantly preparing, with little downtime to enjoy the surroundings. I was so jealous of the guest actors—they’d come for a week or two, spend a few days filming, and the rest of the time they were by the pool with cocktails. Meanwhile, I was working my arse off!" Ardal revealed that producers had warned him about the challenging nature of the role before he started. "They told me, ‘You might last two or three years, but probably not four!’ The producer even painted a bleak picture before I flew out, saying, ‘You know, you can still back out of this.’ He warned about hurricanes, the isolating environment, and even the wildlife." Ultimately, the toll extended beyond work. "After four summers, it began to affect things at home. My family stopped visiting me in Guadeloupe, and that was the real decider for leaving." The actor and comedian, best known for his role in Father Ted, also spoke about his upcoming stand-up tour, which explores themes of identity. "Comedy has become such a diverse platform now, with people discussing their identities—whether it’s race, gender, class, or religion. For me, I was always focused on crafting jokes with a surreal twist. But recently, I’ve been inspired by other comedians to reflect more on who I am, my upbringing, and how technology shapes our identities." Ardal’s departure from Death In Paradise saw Ralf Little take over as DI Neville Parker, a role Little held for five years. Don Gilet is set to debut as the new lead, DI Mervin Wilson, in the upcoming Death In Paradise Christmas special. Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile , select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don’t like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you’re curious, you can read our Privacy Notice. Don't miss the latest news from around Scotland and beyond - Sign up to our daily newsletter here.Can ordinary citizens solve our toughest problems?

Hyderabad: In spite of the Telangana govt expected to fall short of its targeted procurement of fine variety paddy (fine rice) from the kharif crop, the state is not allowing fine rice to be brought in from neighbouring states, including Andhra Pradesh, to procurement centres. Recently, as many as 16 lorries of fine variety paddy were stopped in a night in Khammam on the Telangana-AP border. Traders from Andhra Pradesh and Karnataka are trying to sneak in lorries with fine variety paddy into Telangana as the govt here is offering a 500 bonus per quintal of fine variety paddy, in addition to the minimum support price. The Congress govt needs 36 lakh metric tonnes (LMT) of the fine variety paddy for supply through ration shops. After milling, the state gets 24 lakh metric tonnes of rice. The 24 LMT fine rice is the annual requirement of Telangana to supply rice through ration shops to over 89 lakh ration card holders. If the state falls short of the targeted 36 LMT of fine variety paddy procurement from kharif, it would have to make alternate arrangements to fill up the gap. Till date, the govt has procured 18.07 lakh metric tonnes of fine variety paddy from farmers, and major arrivals of paddy are likely to come to an end by Dec 31. Over 300 check posts armed with CCTV cameras have been set up on the Telangana-AP, Telangana-Karnataka borders and other states. Traders have expressed their ire over the state govt not allowing their paddy-laden trucks to enter Telangana. "As per rules, rice millers have to mandatorily mill 50% of the govt-given paddy, and the remaining 50% they can purchase from the market and mill it," a trader said. However, officials said the main reason for traders flocking to Telangana with paddy stocks is due to the 500 bonus. The name of the farmer, details of the location where paddy was produced, and generation of OTP on the farmer's mobile number are some of the measures being implemented by the civil supplies corporation to check paddy from other states being sold at procurement centres. Civil supplies commissioner DS Chauhan said the 500 bonus was meant only for Telangana farmers and that they would manage fine rice supplies to ration shops as ‘sanna biyyam' (fine rice) in huge quantities was expected to be procured from the ensuing rabi crop too. Chief minister A Revanth Reddy has already announced that the 500 bonus would be extended to fine variety paddy for the ensuing rabi crop too. Stay updated with the latest news on Times of India . Don't miss daily games like Crossword , Sudoku , Location Guesser and Mini Crossword .Police in Suriname Thursday said they had launched a major probe into the death of former president Desi Bouterse, the details surrounding the mysterious emergence of his body at his closely monitored home, where exactly he was hiding and who was protecting him since he fled from justice in mid-January. Stay Connected to the Caribbean Bouterse, 79 was pronounced dead by a doctor at his riverside home on Christmas Day, nearly a year after he had disappeared into hiding hours before he was scheduled to surrender to authorities to begin a 20-year mass murder sentence. The local police, the KPS, said in a social media statement that a criminal investigation is underway and numerous persons are being questioned. The force said it is particularly interested in determining how his body was transported “from an unknown address by unknown persons” to his home in Leonsberg in the capital where relatives, supporters and the leadership of his National Democratic Party (NDP) had gathered to mourn and comfort each other. Police said they were informed before daybreak on Christmas Day that the former military strongman who had staged military coups in 1980 and 1990 and had served two terms as an elected president until 2020, had died and that they were invited to view his remains at his home. How the body got there remains a mystery to frustrated authorities but the police said they then summoned a doctor who pronounced him dead. “According to the doctor, the body showed no signs of foul play and, after consultation with the public prosecution service, was seized for an autopsy to determine the probable cause of death,” the KPS said. “The Suriname police force makes an urgent appeal to society to await the results of the investigation and to refrain from speculation.” His death, five months before general elections are due, came just days after police had stepped up raids at places they believed were linked to Bouterse and as a French newspaper had reported that Bouterse had been hiding out the Commewijne District across the Paramaribo harbor and not in Venezuela as was widely speculated. Bouterse is from that general area. Meanwhile, Waterkant News publication said it had been reliably informed that the death was reported to the Bouterse family “by an unknown indigenous man” but no one can say exactly who the person is. As word spread throughout the country, NDP leaders began arriving at the home before daybreak to view the body, wrapped in a white sheet in a wooden coffin. Viewers were banned from using mobile phones. Police had questioned former first lady Ingrid Bouterse about his hiding place but she maintained ignorance about such details. As the probe continues, a condolence book has been opened from Thursday afternoon for signing at NDP headquarters. As a highly controversial period in local history comes to a close, some regional leaders and political colleagues are reacting to his death. Barbadian Prime Minister Mia Mottley said Bouterse had a strong and dominant persona. “I have met many people since I took office as head of government in May 2018. But some people have a personality that is so powerful that they leave an indelible impression on everyone they come into contact with,” Mottley said of the former military dictator. “Whether you agreed with him or not, you could not ignore the power of his personality. Desi Bouterse, former president of the Republic of Suriname, dominated Surinamese politics for four decades. It was through his eyes and heart that I came to know the rich culture of this melting pot country on the South American continent. That was how my love for Suriname and its people began,” she said.Maryland bullies Bucknell to secure third straight win

Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases Strong balance sheet with approximately $80.0 million of cash and cash equivalents, including proceeds from a PIPE financing co-led by BVF Partners, L.P. and Frazier Life Sciences Cash expected to fund operations into the second half of 2027, including through Phase 3 SELVA clinical trial of QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) and Phase 2 clinical trial in cutaneous venous malformations (cutaneous VMs) Microcystic LMs is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. QTORINTM rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous VMs WAYNE, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the completion of its previously announced merger with Pieris Pharmaceuticals, Inc. (Pieris). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on December 16, 2024, under the ticker symbol "PVLA". Palvella will continue to be led by Wes Kaupinen, its Founder and Chief Executive Officer, and other members of the Palvella management team. The transaction was approved by Pieris stockholders at a special meeting held on December 11, 2024, and the transaction had been previously approved by Palvella stockholders. "With strong support from leading healthcare-dedicated investors, Palvella is well positioned to enter the public markets and pursue our vision of becoming the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases," said Mr. Kaupinen. “This transaction will enable us to accelerate late-stage development of QTORINTM rapamycin, our lead product candidate, for microcystic LMs and cutaneous VMs while also further advancing additional novel product candidates from our QTORINTM platform." Concurrent with the merger, Palvella completed a previously announced oversubscribed $78.9 million private placement co-led by BVF Partners, L.P., an existing investor, and Frazier Life Sciences, a new investor, and with participation from a syndicate of leading healthcare-dedicated investors. Additional new investors include Blue Owl Healthcare Opportunities, Nantahala Capital, DAFNA Capital Management, ADAR1 Capital Management, and a healthcare dedicated fund. Existing investors Samsara BioCapital, Petrichor, CAM Capital, Ligand Pharmaceuticals, Integrated Finance Group (an AscellaHealth partner company), BioAdvance, and Gore Range Capital also participated in the financing. Palvella's cash and cash equivalents of approximately $80.0 million is expected to fund operations into the second half of 2027, including through results from the SELVA Phase 3 clinical trial of QTORINTM rapamycin for the treatment of microcystic LMs and Phase 2 clinical trial of QTORINTM rapamycin in cutaneous VMs. Palvella’s research team developed QTORINTM, a patented and versatile platform designed to generate novel topical therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of serious, rare genetic skin diseases. Well-accepted mechanisms of action of rapamycin and other therapeutic agents represent potential therapies for rare genetic skin diseases. However, the adverse event profile of those agents through systemic exposure poses significant barriers to patient adoption. Palvella’s QTORINTM product candidates are designed for targeted, localized delivery of therapeutic agents to pathogenic tissue of interest while minimizing systemic absorption and thereby reducing the risk of unwanted adverse events associated with systemic therapy. Palvella's lead product candidate QTORINTM rapamycin is a novel, patented 3.9% rapamycin anhydrous gel currently under development for the treatment of microcystic LMs, cutaneous VMs, and other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway. QTORINTM rapamycin has received FDA Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for microcystic LMs and is the recent recipient of up to a $2.6 million FDA Orphan Products Grant. QTORINTM rapamycin has also received Fast Track Designation for venous malformations. QTORINTM rapamycin is protected by issued composition patents covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S., Japan, Australia, China and Israel and pending patent applications broadly covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S. and other countries. In the third quarter of 2024, Palvella initiated SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORINTM rapamycin administered once daily for the treatment of microcystic LMs. The primary efficacy endpoint is the change from baseline in the overall microcystic LM Investigator Global Assessment (mLM-IGA) at week 24. The Phase 3 study is enrolling approximately 40 subjects, age six or older, at leading vascular anomaly centers across the U.S. Transaction Details Based on the final exchange ratio of approximately 0.30946 shares of Pieris common stock for each share of Palvella common stock, at the closing of the merger, there are approximately 13.95 million shares of the combined company's common stock outstanding on a diluted basis, with prior Pieris stockholders owning approximately 11% on a diluted basis and prior Palvella stockholders (including investors in the private placement) holding approximately 89% of the combined company's outstanding common stock on a diluted basis. In connection with the closing of the merger, Pieris issued a non-transferable contingent value right (CVR) to Pieris shareholders of record immediately prior to the closing, which does not include the former holders of shares of Palvella or the private financing investors. Holders of the CVR will be entitled to receive payments from proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals, in addition to other potential licensing agreements involving certain of Pieris' legacy assets, as well as certain potential payments related to historical research and development tax credits, which may or may not be realized. TD Cowen served as lead placement agent and Cantor served as a placement agent for Palvella's concurrent financing. Troutman Pepper Hamilton Sanders LLP served as legal counsel to Palvella. Cooley LLP served as legal counsel to the placement agents. Stifel served as the exclusive financial advisor to Pieris and Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. served as legal counsel to Pieris. About Microcystic Lymphatic Malformations Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mTOR pathway. The disease is characterized by malformed lymphatic vessels that protrude through the skin and persistently leak lymph fluid (lymphorrhea) and bleed, often leading to recurrent serious infections and cellulitis that can cause hospitalization. The natural history of microcystic LMs are persistent and progressive without spontaneous resolution, with symptoms generally worsening during life, including increases in the number and size of malformed vessels that lead to complications and lifetime morbidity. There are currently no FDA-approved treatments for the estimated more than 30,000 diagnosed patients with microcystic LMs in the United States. About Palvella Therapeutics Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORINTM platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin), is currently in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase 2 trial in cutaneous venous malformations. For more information, please visit www.palvellatx.com or follow the Company on LinkedIn. QTORINTM rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency. This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella and Pieris, as well as assumptions made by, and information currently available to, management of Palvella and Pieris. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, the sufficiency of the combined company’s capital resources; the combined company’s cash runway; the expected timing of the closing of the proposed transactions; statements regarding the potential of, and expectations regarding, Palvella’s programs, including QTORINTM rapamycin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity; the expected timing of initiating, as well as the design of Palvella’s Phase 2 clinical trial of QTORINTM rapamycin in cutaneous venous malformations. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the limited operating history of each company; the significant net losses incurred since inception; the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORINTM rapamycin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of the global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella and Pieris to protect their respective intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Pieris’ most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, as well as the registration statement on Form S-4 filed with the SEC by Pieris in connection with the merger. Palvella and Pieris can give no assurance that the conditions to the proposed transactions will be satisfied. Except as required by applicable law, Palvella and Pieris undertake no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. Palvella Therapeutics Contact Information Investors Wesley H. Kaupinen Founder and CEO, Palvella Therapeutics wes.kaupinen@palvellatx.com Media Stephanie Jacobson Managing Director, Argot Partners palvella@argotpartners.comRobots can learn new actions faster thanks to AI techniquesSouth Dakota scores with 12 seconds left to beat FCS top-ranked North Dakota State 29-28

Thousands demand lower rents at Barcelona demo

Previous: jili k.o
Next: 777 jili casino